VOQUZ Labs AG Delivers Strong Preliminary H1 Results and Reaffirms BUY Rating

On August 15, 2024, NuWays AG released a research update on VOQUZ Labs AG, maintaining a BUY recommendation. The target price remains €22.00. The preliminary H1 results reveal significant year-over-year improvements. Sales surged 24.9% to €2.3 million, with substantial contributions from the visoryQ product.

The company’s EBITDA improved to €0.3 million from a negative €0.5 million the previous year, indicating a 12.4% EBITDA margin. This enhancement is attributed to cost-saving measures and higher margins from visoryQ.

Management reaffirmed the FY guidance of 10-20% top-line growth and an EBITDA margin of 15-20%, highlighting potential sales growth and profitability. Future growth is expected from partnerships and new product launches aimed at SAP-ERP clients.

Overall, the recent release supports the positive outlook, positioning VOQUZ Labs AG to benefit from the ongoing market transformation.